Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.
OBJECTIVE
To examine the level of agreement between self- and observer-reported ratings of ADHD symptoms and executive function (EF) behaviors in adults with moderate to severe ADHD and EF deficits.


METHODS
During a 10-week, randomized, double-blind, placebo-controlled study, the effect of lisdexamfetamine dimesylate (LDX) on EF was assessed by self-report and informant report (Behavior Rating Inventory of Executive Function-Adult Version), and ADHD symptoms were assessed by clinician- and informant-rated scales (ADHD Rating Scale IV with adult prompts and Conners' Adult ADHD Rating Scales-Observer Report: Short Version, respectively). Post hoc analysis used Pearson correlations to assess relationships between self- and informant-rated EF and clinician- and informant-rated ADHD symptoms.


RESULTS
Correlations between self-ratings versus informant ratings and clinician versus informant ratings were greater at Week 10/early termination (EF: placebo [0.5231-0.6085], LDX [0.3543-0.5167]; ADHD symptoms: placebo [0.4169], LDX [0.4004]) versus baseline (EF: placebo [0.3208-0.5023], LDX [0.2852-0.3439]; ADHD symptoms: placebo [0.1511], LDX [-0.0408]).


CONCLUSIONS
LDX improved EF and ADHD symptoms, based on participant, informant, and clinician ratings. Increased rater agreement over time may reflect improved symptom awareness.
1 Duke University Medical Center, Durham, NC, USA.|2 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Richard
R
Weisler
3 Red Oak Psychiatry Associates, P.A., Houston, TX, USA.
Lawrence
L
Ginsberg
4 Shire Development LLC, Wayne, PA, USA.
Bryan
B
Dirks
4 Shire Development LLC, Wayne, PA, USA.
Patrick
P
Deas
4 Shire Development LLC, Wayne, PA, USA.
Ben
B
Adeyi
5 New York University School of Medicine and Psychiatry Service, New York VA Harbor Healthcare System, New York, NY, USA.
Lenard A
LA
Adler
D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D001364:Awareness; D000697:Central Nervous System Stimulants / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D056344:Executive Function / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D057566:Self Report; D016896:Treatment Outcome; D055815:Young Adult
D000697:Central Nervous System Stimulants; D000069478:Lisdexamfetamine Dimesylate
attention-deficit/hyperactivity disorder; executive function; lisdexamfetamine